Anti-Tumor endothelial marker 7

Anti-Tumor endothelial marker 7 Chemische Eigenschaften,Einsatz,Produktion Methoden

• Verwenden

  All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.
  
  The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .

• Allgemeine Beschreibung

  Plexin domain-containing protein 1 (PLXDC1) is a transmembrane protein that is expressed in the tumor endothelium. It contains a signal peptide, a nidogen-like domain and a single hydrophobic domain.

• Biochem/physiol Actions

  Plexin domain-containing protein 1 (PLXDC1) interacts with basement membrane protein, nidogen, on the cell surface. It is associated with metastasis of osteogenic sarcoma. PLXDC1 is up-regulated in the blood vessels of solid tumors of colon, lung and oesophageal cancers. It also has an important role in the proliferation of neovascular endothelial cells in the fibrovascular membrane.

Anti-Tumor endothelial marker 7 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(2)Suppliers